Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

URLhttps://firstwordpharma.com/story/6062467
SourceFirstWord Pharma
Date Published09/15/2025

Additional Reshoring Information:

Company/Division name Emergent BioSolutions
Parent companyEmergent Biosolutions
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2025
Domestically, the work will be done:In-house
Capital investment ($):17
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredEMBEXA® (brincidofovir), a Smallpox Antiviral
What domestic positive factors made reshoring more attractive?Government Incentives, Impact on domestic economy
Find Reshoring Articles